Qianglan Lu
Impact in
- Biomaterials top 5%
- Nanoparticle-Based Drug Delivery
- Biomedical Engineering top 5%
- Nanoplatforms for cancer theranostics
Papers in
-
- Nanoplatforms for cancer theranostics 22
-
- Advanced biosensing and bioanalysis techniques 5
- Extracellular vesicles in disease 4
- RNA Interference and Gene Delivery 4
- Co-authors
- Lifang Yang (14 shared papers)Yilin Song (11 shared papers)Nan Li (9 shared papers)Siyu Wang (8 shared papers)Fengping Tan (8 shared papers)Peishan Li (5 shared papers)Shan Yang (5 shared papers)Min Xu (8 shared papers)
In The Last Decade
Qianglan Lu
29 papers receiving 970 citations
Peers
Comparison fields: 5 of 81
- Biomaterials 226
- Biomedical Engineering 725
- Materials Chemistry 443
- Immunology 123
- Biochemistry 38
Countries citing papers authored by Qianglan Lu
This map shows the geographic impact of Qianglan Lu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Qianglan Lu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Qianglan Lu more than expected).
Fields of papers citing papers by Qianglan Lu
This network shows the impact of papers produced by Qianglan Lu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Qianglan Lu. The network helps show where Qianglan Lu may publish in the future.
Co-authors
The 25 scholars most cited alongside Qianglan Lu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 30 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2019 | 112 | |
| 2 | 2020 | 74 | |
| 3 | 2019 | 65 | |
| 4 | 2019 | 62 | |
| 5 | 2019 | 60 | |
| 6 | 2019 | 58 | |
| 7 | 2022 | 56 | |
| 8 | 2020 | 52 | |
| 9 | 2020 | 50 | |
| 10 | 2024 | 45 | |
| 11 | 2019 | 44 | |
| 12 | 2020 | 42 | |
| 13 | 2022 | 33 | |
| 14 | 2019 | 31 | |
| 15 | 2020 | 28 | |
| 16 | 2020 | 26 | |
| 17 | 2020 | 25 | |
| 18 | 2022 | 21 | |
| 19 | 2024 | 20 | |
| 20 | 2024 | 18 |
About Qianglan Lu
Qianglan Lu is a scholar working on Biomedical Engineering, Molecular Biology, Materials Chemistry, Immunology and Biomaterials, having authored 30 papers that have together received 975 indexed citations. Recurring topics across this work include Nanoplatforms for cancer theranostics (22 papers), Advanced Nanomaterials in Catalysis (11 papers), Advanced biosensing and bioanalysis techniques (5 papers), Nanoparticle-Based Drug Delivery (5 papers), Immunotherapy and Immune Responses (5 papers), Extracellular vesicles in disease (4 papers), RNA Interference and Gene Delivery (4 papers) and Cancer Research and Treatments (3 papers). The work is most often cited by research in Biomaterials (226 citations), Biomedical Engineering (725 citations), Materials Chemistry (443 citations), Immunology (123 citations) and Biochemistry (38 citations). Qianglan Lu has collaborated with scholars based in China and Thailand. Frequent co-authors include Lifang Yang, Yilin Song, Nan Li, Siyu Wang, Fengping Tan, Peishan Li, Shan Yang, Min Xu, Yu Cheng and Yujun Song. Their work appears in journals such as ACS Nano, Biomaterials, Nano Research, Acta Pharmaceutica Sinica B and ACS Applied Materials & Interfaces.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.